{
  "docId": "019de073-9947-75c9-ab6d-01a31b39af7e",
  "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f",
  "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides",
  "authorId": "third-harmonic-bio",
  "authorName": "Third Harmonic Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 20,
  "pageCount": 24,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "Includes a patient quote and clinical imagery to emphasize the severity of the condition.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/20",
  "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e",
  "deckJsonHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e.json",
  "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.38,
        "w": 0.485,
        "x": 0.055,
        "y": 0.458
      },
      "kind": "image",
      "text": "Clinical images of urticaria",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f1c2737-cea1-4c38-9449-c5f6923113b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.52,
        "y": 0.235
      },
      "kind": "list",
      "text": "Prevalence: More than 1.5 million patients or 0.5-1% point prevalence; ~70-80% female, mean age ~46 years\nSymptoms: severely itchy, painful wheals and angioedema which confer significant mental health and quality of life burdens\nEtiology: both inducible (caused by specific stimuli/triggers) and spontaneous (no identified stimuli, potentially auto-immune) forms\nCurrent treatment options are limited: oral anti-histamines only effective in about half of patients; single biologic therapy approved for second-line use\nNew treatment options with the potential to achieve robust disease control are imperative to driving awareness, diagnosis and treatment",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "626fe2ca-3ef9-4e1e-8186-24a985e051f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.41,
        "x": 0.045,
        "y": 0.275
      },
      "kind": "quote",
      "text": "Out there, it’s a horrible world for urticaria patients",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a15d82bc-aa42-4e15-a295-617377e719fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.33,
        "x": 0.108,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "1Marcus Mauer MD, LifeSci Immunology and Inflammation Day, May 10, 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1a742eb-77df-4920-9268-9d7aa50d02a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.492,
        "x": 0.036,
        "y": 0.125
      },
      "kind": "title",
      "text": "A severe, yet undertreated dermal inflammatory condition",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "066f6cce-cd46-4883-8960-9073b35718fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.038,
        "w": 0.448,
        "x": 0.036,
        "y": 0.068
      },
      "kind": "title",
      "text": "Chronic Urticaria Disease Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e35e189f-13c2-4e51-9332-efe543935d6a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "0eb71c1a-ae3e-4aa6-8482-8538df98172f",
      "evidence": "The Chronic Urticaria Disease Overview effectively frames the problem with bulleted points and supporting data.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 21,
      "from": 20,
      "beatId": "3071eeb1-d844-41d8-a60d-a94623bcd39f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The deck presents an overview of the market size on pages 20 and 21, discussing chronic urticaria and severe asthma.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1637e937-fd9b-4682-939c-d684884ac925",
      "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.",
      "position": 0,
      "objective": "What is the cost of not treating mast cell-mediated diseases effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 24,
      "from": 18,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "f318ece6-0617-4060-a8a8-460a299bc4cc",
      "evidence": "The deck presents multiple upcoming clinical catalysts and a clear development plan.",
      "position": 1,
      "objective": "Can THB001 achieve quick wins and make a big impact in the treatment of mast cell-mediated diseases?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}